Assignee
ARAGON PHARMACEUTICALS INC
US·33 granted patents·19 pending applications·104 citations·filing 2013–2025
Top patents by PatentIndex Score
52 records- 0194US9340524B2Androgen receptor modulator and uses thereofARAGON PHARMACEUTICALS INC·Filed 2014·Granted May 17, 2016·25 cites·4 claims
- 0291US11160796B2Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancerARAGON PHARMACEUTICALS INC·Filed 2020·Granted Nov 2, 2021·5 cites·11 claims
- 0391US10285948B2Anticancer compositionsARAGON PHARMACEUTICALS INC·Filed 2015·Granted May 14, 2019·4 cites·43 claims
- 0491US10052314B2Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancerARAGON PHARMACEUTICALS INC·Filed 2017·Granted Aug 21, 2018·8 cites·25 claims
- 0589US10702508B2Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancerARAGON PHARMACEUTICALS INC·Filed 2018·Granted Jul 7, 2020·6 cites·10 claims
- 0689US9481664B2Androgen receptor modulators and uses thereofARAGON PHARMACEUTICALS INC·Filed 2015·Granted Nov 1, 2016·8 cites·42 claims
- 0789US2025092011A1Crystalline Forms Of An Androgen Receptor ModulatorARAGON PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0888US11224575B2Anticancer compositionsARAGON PHARMACEUTICALS INC·Filed 2019·Granted Jan 18, 2022·2 cites·28 claims
- 0988US10799489B2Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancerARAGON PHARMACEUTICALS INC·Filed 2019·Granted Oct 13, 2020·4 cites·18 claims
- 1088US9884054B2Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancerARAGON PHARMACEUTICALS INC·Filed 2013·Granted Feb 6, 2018·8 cites·19 claims
- 1186US12303493B2Anticancer compositionsARAGON PHARMACEUTICALS INC·Filed 2024·Granted May 20, 2025·0 cites·30 claims
- 1286USRE49353EAnti-androgens for the treatment of non-metastatic castrate-resistant prostate cancerARAGON PHARMACEUTICALS INC·Filed 2020·Granted Jan 3, 2023·1 cites·55 claims
- 1386US10849888B2Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancerARAGON PHARMACEUTICALS INC·Filed 2018·Granted Dec 1, 2020·3 cites·15 claims
- 1486US10799488B2Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancerARAGON PHARMACEUTICALS INC·Filed 2019·Granted Oct 13, 2020·3 cites·19 claims
- 1585US11491149B2Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancerARAGON PHARMACEUTICALS INC·Filed 2020·Granted Nov 8, 2022·2 cites·10 claims
- 1685US10934271B2Crystalline forms of an androgen receptor modulatorARAGON PHARMACEUTICALS INC·Filed 2020·Granted Mar 2, 2021·1 cites·17 claims
- 1785US9481663B2Crystalline forms of an androgen receptor modulatorARAGON PHARMACEUTICALS INC·Filed 2013·Granted Nov 1, 2016·5 cites·21 claims
- 1884US11963952B2Anti-androgens for the treatment of metastatic castration-sensitive prostate cancerARAGON PHARMACEUTICALS INC·Filed 2023·Granted Apr 23, 2024·2 cites·8 claims
- 1984US10308630B2Crystalline forms of an androgen receptor modulatorARAGON PHARMACEUTICALS INC·Filed 2018·Granted Jun 4, 2019·2 cites·9 claims
- 2083USRE50642EAnti-androgens for the treatment of non-metastatic castrate-resistant prostate cancerARAGON PHARMACEUTICALS INC·Filed 2022·Granted Oct 21, 2025·0 cites·56 claims
- 2182US10316015B2Processes for the preparation of a diarylthiohydantoin compoundARAGON PHARMACEUTICALS INC·Filed 2015·Granted Jun 11, 2019·4 cites·50 claims
- 2280US10723714B2Processes for the preparation of a diarylthiohydantoin compoundARAGON PHARMACEUTICALS INC·Filed 2019·Granted Jul 28, 2020·1 cites·39 claims
- 2380US2024293321A1Anticancer compositionsARAGON PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 2478US10766875B2Crystalline forms of an androgen receptor modulatorARAGON PHARMACEUTICALS INC·Filed 2019·Granted Sep 8, 2020·0 cites·19 claims
- 2578US9617602B2Methods and compositions for determining resistance to androgen receptor therapyARAGON PHARMACEUTICALS INC·Filed 2013·Granted Apr 11, 2017·6 cites·31 claims
- 2678US2024100033A1Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate CancerARAGON PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2777US12018008B2Crystalline forms of an androgen receptor modulatorARAGON PHARMACEUTICALS INC·Filed 2021·Granted Jun 25, 2024·0 cites·41 claims
- 2877US9994545B2Crystalline forms of an androgen receptor modulatorARAGON PHARMACEUTICALS INC·Filed 2016·Granted Jun 12, 2018·1 cites·21 claims
- 2976US2023233529A1Anticancer compositionsARAGON PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3075US2023022446A1Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate CancerARAGON PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
- 3173US11911511B2Anticancer compositionsARAGON PHARMACEUTICALS INC·Filed 2021·Granted Feb 27, 2024·0 cites·37 claims
- 3273US11040953B2Process for the preparation of a diarylthiohydantoin compoundARAGON PHARMACEUTICALS INC·Filed 2020·Granted Jun 22, 2021·0 cites·3 claims
- 3372US10556882B2Crystalline forms of an androgen receptor modulatorARAGON PHARMACEUTICALS INC·Filed 2019·Granted Feb 11, 2020·0 cites·19 claims
- 3472US10526310B2Crystalline forms of an androgen receptor modulatorARAGON PHARMACEUTICALS INC·Filed 2019·Granted Jan 7, 2020·0 cites·21 claims
- 3572US2021000812A1Anti-Androgens For The Treatment Of Non-Metastatic Castrate-Resistant Prostate CancerARAGON PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 3671US12303497B2Anti-androgens for the treatment of metastatic castration-sensitive prostate cancerARAGON PHARMACEUTICALS INC·Filed 2023·Granted May 20, 2025·0 cites·12 claims
- 3770US2022151931A1Anticancer compositionsARAGON PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 3868US9688655B2Process for the preparation of a diarylthiohydantoin compoundARAGON PHARMACEUTICALS INC·Filed 2015·Granted Jun 27, 2017·3 cites·22 claims
- 3968US2021093620A1Anti-Androgens For The Treatment Of Non-Metastatic Castration-Resistant Prostate CancerARAGON PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4065US2021177821A1Androgen Receptor Modulator And Uses ThereofARAGON PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 4161US2023338351A1Androgen Receptor Inhibitors For The Treatment Of Non-Metastatic Castration-Resistant Prostate Cancer In Subjects With Severe Hepatic ImpairmentARAGON PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 4257US2017360754A1Anticancer compositionsARAGON PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 4357US2025345319A1Anticancer CompositionsARAGON PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 4456US11723898B2Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairmentARAGON PHARMACEUTICALS INC·Filed 2020·Granted Aug 15, 2023·0 cites·39 claims
- 4556US2016220548A1Androgen receptor modulator and uses thereofARAGON PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 4655US10023556B2Androgen receptor modulators and uses thereofARAGON PHARMACEUTICALS INC·Filed 2016·Granted Jul 17, 2018·0 cites·19 claims
- 4752US2021137903A1Anti-androgens for the treatment of prostrate cancerARAGON PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4850US2022160695A1Anti-androgens for the treatment of metastatic castration-sensitive prostate cancerARAGON PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 4948US2017360707A1Anticancer compositionsARAGON PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 5040US2017196840A1Methods and compositions for determining resistance to androgen receptor therapyARAGON PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
Showing the top 50 of 52 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when ARAGON PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →